ClinicalTrials.gg
CompletedNCT00171535Updated Nov 8, 2011

Efficacy and Safety of Valsartan/Amlodipine Combination in Patients With Severe Hypertension

A Phase 3 interventional study of valsartan/amlodipine in Hypertension, sponsored by Novartis. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-11-08.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.

Enrollment
82nd of 139
130 · median 198
Started
2004
with 23 others
Phase 3
53 of 140
none open now
Registered
23rd of 140
by date
Lead sponsor
69 of 140
Novartis

Among the 140 studies testing valsartan in Hypertension, this one is the 82nd largest by enrollment of the 139 interventional ones that give a count, is one of 24 that started in 2004, is one of 53 in phase 3, and was the 23rd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →

About valsartan

Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 140 studies testing valsartan in Hypertension as a file.
02

Study summary

This study will assess the effectiveness and safety of different combination antihypertensive treatments in patients with severe hypertension

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • hypertension
  • high blood pressure
  • valsartan
  • amlodipine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with severe hypertension

Exclusion criteria

Exclusion Criteria:

  • History of stroke, myocardial infarction, heart failure, chest pain, abnormal heart rhythm
  • Liver, kidney, or pancreas disease
  • Insulin dependent diabetes
  • Allergy to certain medications used to treat high blood pressure

Other protocol-defined inclusion/exclusion criteria may apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
130 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse events and serious adverse events at each study visit for 6 weeks

Secondary outcomes

  1. Sitting and standing blood pressure measurements after 6 weeks

  2. Laboratory test data after 6 weeks

  3. Vital signs at each study visit for 6 weeks

07

Study locations

1 site
  • Novartis Pharmaceuticals
    East Hanover, New Jersey 07936, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2004, a primary completion of Apr 2005 and a completion of Apr 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 15, 2005
Start
Oct 2004
Primary completionActual
Apr 2005
CompletionActual
Apr 2005
Last update
Nov 8, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00171535
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Sep 15, 2005
Start date
Oct 2004
Primary completion
Apr 2005
Completion
Apr 2005
Last update
Nov 8, 2011

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Valsartan · Amlodipine

Start the discussion